SELLAS Life Sciences Group, Inc.
Begin enrollment in the first-line AML trial for SLS009
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 12 Aug 2025
- Due
- 31 Mar 2026
- Delivered
- Q1 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The randomized 80-patient trial is currently in preparation and is expected to begin enrollment by Q1 2026.”
What we found
Evidence strength A What the grades mean
The company confirmed in its SEC filings that the randomized Phase 2 clinical trial for SLS009 in first-line AML began enrollment during the first quarter of 2026.
-
A SELLAS Life Sciences Group, Inc. 10-Q filed 2026-05-12
“The randomized 80-patient Phase 2 clinical trial is currently ongoing and began enrollment in the first quarter of 2026.” ✓ confirmed on the page
Market reaction: the shares moved +40.1% against the S&P 500 over the three sessions around the disclosure (11 May 2026 to 14 May 2026). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- Enrollment in SLS009 first-line AML trial
- Target
- 80 patients
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you SELLAS Life Sciences Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-SLS-002050 · Corrections policy